The 36-month beta value for ORIC is at 1.11. Analysts have varying views on the stock, with 3 analysts rating it as a “buy,” 7 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ORIC is 46.01M, and currently, shorts hold a 26.65% of that float. The average trading volume for ORIC on October 23, 2024 was 442.20K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
ORIC) stock’s latest price update
ORIC Pharmaceuticals Inc (NASDAQ: ORIC) has seen a rise in its stock price by 3.33 in relation to its previous close of 8.71. However, the company has experienced a -6.74% decline in its stock price over the last five trading sessions. globenewswire.com reported 2024-10-09 that SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 09, 2024 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that the company will present a poster at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics to be held October 23-25, 2024, in Barcelona, Spain.
ORIC’s Market Performance
ORIC Pharmaceuticals Inc (ORIC) has experienced a -6.74% fall in stock performance for the past week, with a -16.28% drop in the past month, and a -19.93% drop in the past quarter. The volatility ratio for the week is 4.74%, and the volatility levels for the past 30 days are at 5.17% for ORIC. The simple moving average for the past 20 days is -5.88% for ORIC’s stock, with a -11.66% simple moving average for the past 200 days.
Analysts’ Opinion of ORIC
Many brokerage firms have already submitted their reports for ORIC stocks, with Stifel repeating the rating for ORIC by listing it as a “Buy.” The predicted price for ORIC in the upcoming period, according to Stifel is $20 based on the research report published on September 06, 2024 of the current year 2024.
Wedbush gave a rating of “Outperform” to ORIC, setting the target price at $8 in the report published on September 22nd of the previous year.
ORIC Trading at -8.68% from the 50-Day Moving Average
After a stumble in the market that brought ORIC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -45.95% of loss for the given period.
Volatility was left at 5.17%, however, over the last 30 days, the volatility rate increased by 4.74%, as shares sank -10.00% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +1.81% upper at present.
During the last 5 trading sessions, ORIC fell by -6.74%, which changed the moving average for the period of 200-days by +9.22% in comparison to the 20-day moving average, which settled at $9.56. In addition, ORIC Pharmaceuticals Inc saw -2.17% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ORIC starting from Chacko Jacob, who sale 40,000 shares at the price of $16.21 back on Mar 06 ’24. After this action, Chacko Jacob now owns 728,544 shares of ORIC Pharmaceuticals Inc, valued at $648,380 using the latest closing price.
Chacko Jacob, the PRESIDENT AND CEO of ORIC Pharmaceuticals Inc, sale 26,042 shares at $12.29 during a trade that took place back on Feb 07 ’24, which means that Chacko Jacob is holding 768,544 shares at $320,186 based on the most recent closing price.
Stock Fundamentals for ORIC
Current profitability levels for the company are sitting at:
- -81.35 for the present operating margin
- 0.32 for the gross margin
The net margin for ORIC Pharmaceuticals Inc stands at -72.03. The total capital return value is set at -0.4. Equity return is now at value -38.79, with -35.69 for asset returns.
Based on ORIC Pharmaceuticals Inc (ORIC), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -36.14. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -63.0.
Currently, EBITDA for the company is -109.75 million with net debt to EBITDA at 0.38. When we switch over and look at the enterprise to sales, we see a ratio of 389.54. The liquidity ratio also appears to be rather interesting for investors as it stands at 15.08.
Conclusion
In conclusion, ORIC Pharmaceuticals Inc (ORIC) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
